» Articles » PMID: 30613166

Practical Steps to Improve Chronic Hepatitis C Treatment in People with Opioid Use Disorder

Overview
Journal Hepat Med
Publisher Dove Medical Press
Specialty Gastroenterology
Date 2019 Jan 8
PMID 30613166
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: People with a history of injecting drugs have high prevalence of hepatitis C virus (HCV) infection, and many have opioid use disorder (OUD). Modern HCV therapies with improved efficacy and tolerability are available, but access is often limited for this group, who may be underserved for health care and face social inequity. This work develops practical steps to improve HCV care in this population.

Methods: Practical steps to improve HCV care in OUD populations were developed based on clinical experience from Spain, structured assessment of published evidence.

Results: Options for improving care at engagement/screening stages include patient education programs, strong provider-patient relationship, peer support, and adoption of rapid effective screening tools. To facilitate work up/treatment, start options include simplified work up process, integration of HCV and OUD care, and continuous psychosocial support prior, during, and after HCV treatment.

Conclusion: It is important to plan on local basis to set up a joint integrated approach between specific drug treatment services and local points of HCV care. The elements for a specific integrated program should be chosen from options identified, including education services, peer input, organization to make HCV screening and treatment easier by co-location of services, and wider access to prescribing direct-acting antiviral (DAA) therapy.

Citing Articles

Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management.

Grau-Lopez L, Marcos-Fosch C, Daigre C, Palma-Alvarez R, Rando-Segura A, Llaneras J Therap Adv Gastroenterol. 2021; 14:17562848211016563.

PMID: 34471422 PMC: 8404622. DOI: 10.1177/17562848211016563.


Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.

Aghemo A, Horsmans Y, Bourgeois S, Bondin M, Gschwantler M, Hofer H Infect Dis Ther. 2021; 10(4):2203-2222.

PMID: 34125405 PMC: 8572930. DOI: 10.1007/s40121-021-00455-1.


Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City.

Muncan B, Jordan A, Perlman D, Frank D, Ompad D, Walters S Subst Use Misuse. 2021; 56(5):728-737.

PMID: 33682610 PMC: 8514132. DOI: 10.1080/10826084.2021.1892142.


Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine.

Parsons G, Ragbir C, DAgnone O, Gibbs A, Littlewood R, Hard B Subst Abuse Rehabil. 2020; 11:41-47.

PMID: 33173372 PMC: 7648142. DOI: 10.2147/SAR.S266838.


Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment.

Torrens M, Soyemi T, Bowman D, Schatz E BMC Infect Dis. 2020; 20(1):702.

PMID: 32972393 PMC: 7517680. DOI: 10.1186/s12879-020-05426-4.


References
1.
Strathdee S, Latka M, Campbell J, ODriscoll P, Golub E, Kapadia F . Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005; 40 Suppl 5:S304-12. PMC: 2196220. DOI: 10.1086/427445. View

2.
Grebely J, Bruggmann P, Backmund M, Dore G . Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013; 57 Suppl 2:S29-31. DOI: 10.1093/cid/cit264. View

3.
Treloar C, Rance J, Backmund M . Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis. 2013; 57 Suppl 2:S51-5. DOI: 10.1093/cid/cit263. View

4.
Hagedorn H, Rettmann N, Dieperink E, Knott A, Landon B . A Training Model for Implementing Hepatitis Prevention Services in Substance Use Disorder Clinics: A Qualitative Evaluation. J Gen Intern Med. 2015; 30(8):1215-21. PMC: 4510217. DOI: 10.1007/s11606-015-3317-3. View

5.
European Association For The Study Of The Liver . Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218]. J Hepatol. 2022; 78(2):452. DOI: 10.1016/j.jhep.2022.10.006. View